The residues, shown above, alter the function of Major Prion Protein's ability to re-fold, however their positions on the wild-type monomer and fully unfolded PrPSc, do not illustrate a clear mechanism for propagation. The dimer brings light to these residues influence on the infectious qualities of the disease causing residues.
It is theorized from this dimeric structure that the dimerization is the first step in amyloid formation and the presence of these dimers could possibly speed up the aggregation of PrPSc.
The following interactions and residue switching portray possible catalytic sites:
Residues 129, 200, and 164 to 170 are shown to exist right at the dimer interfaces (as noted in the previous structures). The location of these residues within the dimer indicates that their key operation is found somewhere in the dimerization process. [1][2][3]
Helix 1 (Ser 143−Tyr 157) exists at the dimer interface. Many nonpolar residues form Van der Waals attractions. Acidic and mostly negative residues are shown in blue. Basic and mostly positive residues are shown in red. The interactions between these also stabilize the dimer interface.
Helix 2 (Asn 171−Thr 188) is linked to the C-terminal helix 3 (Thr 199−Tyr 225). Van der Waals forces are here between such nonpolar residues as valine, isoleucene, and nonpolar sections as histadine, methionine, and glutamic acid.[2]
The switch region (residues 189-198) is where the actual unfolding has taken place.
More Van der Waals and electrostatic forces occur between the switch region and helix 1 of the same molecule. These interactions would not be able to occur in the monomer.
Dimer interface hydrogen bonding between the dimers exist at Thr188 O−Gly195 N, Thr190 O−Lys194 N and Thr192 O−Thr192 N
Hydrogen bonding between Asp 202 and Thr 199 stabilize the dimeric structure.
Arg 220 and Ser 132 form a hydrogen bond located at the end of helix 3 and near the switch region of the other chain, which allow the inter-chain interactions to be specific.
Due to the importance of initial dimerization in the formation of prion aggregates, the step of dimerization presents a known step for treatments to target.[2]
- ↑ Lee S, Antony L, Hartmann R, Knaus KJ, Surewicz K, Surewicz WK, Yee VC. Conformational diversity in prion protein variants influences intermolecular beta-sheet formation. EMBO J. 2010 Jan 6;29(1):251-62. Epub 2009 Nov 19. PMID:19927125 doi:10.1038/emboj.2009.333
- ↑ 2.0 2.1 2.2 Knaus KJ, Morillas M, Swietnicki W, Malone M, Surewicz WK, Yee VC. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat Struct Biol. 2001 Sep;8(9):770-4. PMID:11524679 doi:10.1038/nsb0901-770
- ↑ Zhang Y, Swietnicki W, Zagorski MG, Surewicz WK, Sonnichsen FD. Solution structure of the E200K variant of human prion protein. Implications for the mechanism of pathogenesis in familial prion diseases. J Biol Chem. 2000 Oct 27;275(43):33650-4. PMID:10954699 doi:10.1074/jbc.C000483200